Month: February 2024

Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at DDW 2024 being held in Washington, D.C., May 18-21, 2024. The details of the poster presentation are as follows: Title: LOCAL BIOACTIVATION AND EFFICACY OF PALI-2108: A PROMISING PDE4 INHIBITOR PRODRUG FOR ULCERATIVE COLITIS TREATMENT Session: Animal Models of IBD: Pre-Clinical Treatment of Intestinal Inflammation Date & Time: May 21, 2024 from 12:30 PM to 1:30 PM EDT (UTC –4) For more information about DDW 2024, please visit the conference website. About Palisade Bio Palisade Bio is a biopharmaceutical company focused...

PHOENIX, Feb. 15, 2024 (GLOBE NEWSWIRE) — Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, will hold a conference call on Thursday, March 7, 2024 at 1:00 p.m. Eastern time to discuss results for the fourth quarter and full year ended December 31, 2023. The financial results will be issued in a press release prior to the call. Global Water Resources management will host the presentation, followed by a question-and-answer period. Date: Thursday, March 7, 2024Time: 1:00 p.m. Eastern time (10:00 a.m. Pacific time)Toll-free dial-in number: 1-833-816-1435International dial-in number: 1-412-317-0527Conference ID: 10186360Webcast (live and replay): here The conference call webcast is also available via a link in the Investors section of the company’s website at www.gwresources.com. Please call...

VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) — Foremost Lithium Resource & Technology Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost Lithium”, “Foremost” or the “Company”), a North American hard-rock lithium exploration company, today announced the appointment of seasoned finance and accounting executive Sead Hamzagic, CPA, CGA as Chief Financial Officer and Corporate Secretary. Mr. Hamzagic is a Chartered Professional Accountant, Certified General Accountant, has over 37 years of public practice accounting and financial management experience as a director and/or Chief Financial Officer with multiple public companies listed on Nasdaq, the TSX-V and the CSE – with a particular emphasis on natural resource and mining companies. His experience includes initial public offerings, reverse takeovers and plans of arrangements....

The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular (IM) injection. Anaphylm candidate, with the potential to be the first and only non-invasive, orally delivered epinephrine product, demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the emergency treatment of severe allergic reactions, including anaphylaxis. A Phase 3 pivotal study for Anaphylm is currently underway with topline data anticipated in the first quarter of 2024.WARREN, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’...

Mendoza 1Luis Carlos MendozaATLANTA, Feb. 15, 2024 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray”) (NYSE: GTN) announces the launch of InvestigateTV+ en Español on February 26, 2024, in 26 of Gray’s Telemundo markets. The program from Gray’s award-winning investigative team, which currently airs in English in 113 of Gray’s markets, will now reach an extended audience through its newly formatted show in Spanish. Airing Monday through Friday in early news windows across the country, the show will provide in-depth, informative, and inspirational stories in Spanish that aim to dig deeper into storytelling while providing viewers with solutions.“An essential part of Gray’s mission is investigative journalism, and it is our goal for everyone to see it. Whether a viewer speaks Spanish or English, we want to give viewers the...

Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, with topline results expected mid-2024. CAPE CANAVERAL, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results, which support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease, were published in the Journal of Lipid Research...